Get the Stockscreener App
17.42
1.75%
0.30
Pre-market:
17.43
0.010
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $17.42, with a volume of 13.74M.
It is up +1.75% in the last 24 hours and up +5.32% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$17.12
Open:
$17.05
24h Volume:
13.74M
Relative Volume:
1.49
Market Cap:
$20.01B
Revenue:
$14.57B
Net Income/Loss:
$-296.50M
P/E Ratio:
-67.26
EPS:
-0.259
Net Cash Flow:
$1.64B
1W Performance:
+1.69%
1M Performance:
+5.32%
6M Performance:
+30.39%
1Y Performance:
+79.40%
1-Day Range:
$17.00
$17.45
1-Week Range:
$16.86
$17.59
52-Week Range:
$9.425
$18.39
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.42 | 20.01B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 59.37B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 46.91B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.04B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
472.21 | 20.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Is Viatris Stock Outperforming the S&P 500? - finance.yahoo.com
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - Stock Traders Daily
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - marketscreener.com
Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com
Oppenheimer initiates Viatris stock with outperform rating - Investing.com
Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com UK
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - finance.yahoo.com
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Piper Sandler raises Viatris stock price target on patch growth - Investing.com
Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PR Newswire
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - finance.yahoo.com
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews
Viatris' China Policy Concerns Overstated, UBS Says - Moomoo
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Healthcare Giant with a 13.99% Upside and Strategic Collaborations - DirectorsTalk Interviews
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris Inc (VTRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Viatris Inc. (VTRS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine? - Yahoo Finance
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Davis Selected Advisers (VTRS) discloses 75.2M-share, 6.5% stake in Viatris Inc - Stock Titan
ETFs Investing in Viatris, Inc. Stocks - TradingView
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - TradingView
Harrow adds TYRVAYA's global rights to dry eye portfolio - Glance by Eyes On Eyecare
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):